You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

Investigational Drug Information for Saroglitazar


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Saroglitazar?

Saroglitazar is an investigational drug.

There have been 17 clinical trials for Saroglitazar. The most recent clinical trial was a Phase 2 trial, which was initiated on July 20th 2023.

The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Liver Diseases. The leading clinical trial sponsors are Zydus Therapeutics Inc., Zydus Discovery DMCC, and Command Hospital, India.

There are twelve US patents protecting this investigational drug and two hundred and seventy-eight international patents.

Recent Clinical Trials for Saroglitazar
TitleSponsorPhase
A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With ComorbiditiesZydus Lifesciences LimitedPhase 4
Saroglitazar Magnesium 4 mg for NASH in People Living With HIV in the USZydus Therapeutics Inc.Phase 2
Saroglitazar Magnesium for Treatment of Primary Biliary CholangitisZydus Therapeutics Inc.Phase 2/Phase 3

See all Saroglitazar clinical trials

Clinical Trial Summary for Saroglitazar

Top disease conditions for Saroglitazar
Top clinical trial sponsors for Saroglitazar

See all Saroglitazar clinical trials

US Patents for Saroglitazar

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Saroglitazar ⤷  Subscribe Fused triterpene compounds and uses thereof PIRAMAL ENTERPRISES LIMITED (Mumbai, IN) ⤷  Subscribe
Saroglitazar ⤷  Subscribe Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Subscribe
Saroglitazar ⤷  Subscribe Combination GENESIS PHARMA SA (Athens, GR) ⤷  Subscribe
Saroglitazar ⤷  Subscribe Monocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP) ⤷  Subscribe
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Saroglitazar

Drugname Country Document Number Estimated Expiration Related US Patent
Saroglitazar Argentina AR097067 1989-12-31 ⤷  Subscribe
Saroglitazar Australia AU2014294548 1989-12-31 ⤷  Subscribe
Saroglitazar Brazil BR112015031878 1989-12-31 ⤷  Subscribe
Saroglitazar Canada CA2917923 1989-12-31 ⤷  Subscribe
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.